Thrombostatin Inhibits Induced Canine Coronary Thrombosis

Summary

Thrombostatin (RPPGF), an angiotensin converting enzyme metabolite of bradykinin, is an inhibitor of α-thrombin’s ability to activate platelets. We examined the in vivo pharmacokinetics and pharmacodynamics of thrombostatin in rabbits and its ability to inhibit coronary thrombosis induced by electrolytic injury in dogs. Plasma half-life of thrombostatin had a t_1/2α of 2.6 min and a t_1/2β of 24 min in rabbits. Ligating the renal arteries did not prolong clearance (t_1/2α = 2.4 min; t_1/2β = 12 min). Thrombostatin produced a prolonged in vivo antiplatelet effect. At 30 min after a single intravenous administration in rabbits, thrombostatin’s plasma concentration was <8.7 μM (5 μg/ml). However, ex vivo 20 and 40 nM γ-thrombin-induced platelet aggregation of these rabbits’ platelets was inhibited 40% for 2.75 and 1 h, respectively. In vitro, flow cytometry studies revealed that thrombostatin specifically bound to human platelets and washed human platelets treated with thrombostatin were less responsive to γ-thrombin than control platelets. Using electrolytic injury to induce coronary artery thrombosis, dogs treated with thrombostatin, aspirin, or combined thrombostatin and aspirin occluded in 62 ± 25 (mean ± SD), 62 ± 36, or 89 ± 32 min versus untreated animals which occluded at 39 ± 27 min, (p <0.01, p <0.01 and p <0.001, respectively). These studies show that thrombostatin binds to platelets and can delay coronary occlusion in vivo.

Abbreviations: RPPGF: thrombostatin; PAR1: protease activated receptor 1, the first cloned thrombin receptor; PRP: platelet-rich plasma; PPP: plateletpoor plasma; LCX: left circumflex coronary artery; APTT: activated partial thromboplastin time; PT: prothrombin time

• References

• 1 Shima C, Majiima M, Katori M. A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 1992; 60: 111-9.
• 2 Majima M, Sunhara N, Harada Y, Katori M. Detection of the degradation products for bradykinin by enzyme immunoassays as markers for the release of kinin in vivo . Biochem Pharmacol 1993; 45: 559-67.
• 3 Hasan AAK, Amenta S, Schmaier AH. Bradykinin and its metabolite, ARG-PRO-PRO-GLY-PHE, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 1996; 94: 517-28.
• 4 Meloni FJ, Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991; 266: 6786-94.
• 5 Jiang Y, Muller-Esterl W, Schmaier AH. Domain 3 of kininogens contains a cell binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-7.
• 6 Puri RN, Zhou F, Hu C-J, Colman RF, Colman RW. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-7.
• 7 Vu T-Kh, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
• 8 Hasan AAK, Krishnan R, Tulinsky A, Srikanth S, Schmaier AH. The mechanism of thrombostatin’s inhibition of thrombin-induced platelet activation. Circulation 1998; 98 (Suppl. 01) I-800.
• 9 August DA, Verma N, Vaertan MA, Shah R, Brenner DE. An evaluation of hepatic extraction and clearance of doxorubicin. Br J Cancer 1995; 72: 65-71.
• 10 Rowland M, Tozer T. Clinical pharmacokinetics: concepts and applications. 2nd edition. Philadelphia: Lea & Febiger; 1989
• 11 Rebello S, Blank HS, Rote WE, Vlasuk GP, Lucchesi BR. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration. J Pharm Exp Therap 1997; 283: 91-9.
• 12 Romson SS, Haack DW, Lucchesi BR. Electric induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980; 17: 841-53.
• 13 Mickelson JK, Hoff PT, Lucchesi BR. High dose IV aspirin, not low dose IV or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol 1993; 21: 502-20.
• 14 Schmaier AH, Dahl LD, Rozemuller AJM, Roos RAC, Wagner SL, Chung R, Van Nostrand WE. Protease nexin-2/amyloid β protein precursor. A tight binding inhibitor of coagulation factor IXa J Clin Invest 1993; 92: 2540-5.